Nephrology Medical News about renal cell cancer

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. 2008 Exclusive Survey—Earnings: Good news for primary care income

3. Medicare pay-for-reporting effort draws fire from frustrated doctors

4. Allopurinol-induced recurrent dress syndrome: Pathophysiology and treatment

5. Debunking Myths in the US Healthcare System

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Sorafenib reveals efficacy in sequential treatment of metastatic renal cell cancer
Expert Review of Anticancer Therapy, 10/21/09

Merseburger AS et al. – Metastatic renal cell carcinoma (mRCC) is a highly vascularized tumor with a generally poor prognosis. It is largely resistant to conventional cancer treatment, including most schemes of hormonal and cytokine therapy as well as to modern chemotherapy. Regarding current investigations, the aim of the present article is to address and critically discuss the clinical data concerning the efficacy of sorafenib as part of a sequential treatment of mRCC.

<< Previous
Angio-Embolization of Renal Artery Pseudoaneurysm after Renal...

Next >>
Preoperative Erythrocyte Sedimentation Rate Is an Independent...

The Expression of Thrombospondin-1 and p53 in Clear Cell Renal Cell Carcinoma: Its Relationship to Angiogenesis, Cell Proliferation and Cancer Specific Survival
The Journal of Urology, 10/14/09 Relevance Score: 83%

MK591, a leukotriene biosynthesis inhibitor, induces apoptosis in prostate cancer cells: Synergistic action with LY294002, an inhibitor of phosphatidylinositol 3?-kinase
Cancer Letters, 11/16/09 Relevance Score: 81%

Outcome after thyroid surgery for metastasis from renal cell cancer
Surgery, 11/03/09 Relevance Score: 81%

Overexpression of myosin VI in prostate cancer cells enhances PSA and VEGF secretion, but has no effect on endocytosis
Oncogene, 10/29/09 Relevance Score: 81%

High-Throughput Cell-Based Screening of 4910 Known Drugs and Drug-like Small Molecules Identifies Disulfiram as an Inhibitor of Prostate Cancer Cell Growth
Clinical Cancer Research, 10/06/09 Relevance Score: 81%